- Home
- INV vs QURE Comparison
INV vs QURE Comparison
Compare INV & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INV
- QURE
- Stock Information
- Founded
- INV 2015
- QURE 1998
- Country
- INV United States
- QURE Netherlands
- Employees
- INV N/A
- QURE N/A
- Industry
- INV
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- INV
- QURE Health Care
- Exchange
- INV NYSE
- QURE Nasdaq
- Market Cap
- INV 448.7M
- QURE 432.6M
- IPO Year
- INV N/A
- QURE 2007
- Fundamental
- Price
- INV $11.49
- QURE $7.33
- Analyst Decision
- INV
- QURE Buy
- Analyst Count
- INV 0
- QURE 6
- Target Price
- INV N/A
- QURE $17.00
- AVG Volume (30 Days)
- INV 17.8K
- QURE 699.6K
- Earning Date
- INV 11-14-2024
- QURE 11-05-2024
- Dividend Yield
- INV N/A
- QURE N/A
- EPS Growth
- INV N/A
- QURE N/A
- EPS
- INV N/A
- QURE N/A
- Revenue
- INV $945,000.00
- QURE $28,587,000.00
- Revenue This Year
- INV N/A
- QURE $178.43
- Revenue Next Year
- INV N/A
- QURE $49.15
- P/E Ratio
- INV N/A
- QURE N/A
- Revenue Growth
- INV 18.58
- QURE N/A
- 52 Week Low
- INV $8.55
- QURE $3.73
- 52 Week High
- INV $18.75
- QURE $11.35
- Technical
- Relative Strength Index (RSI)
- INV N/A
- QURE 61.28
- Support Level
- INV N/A
- QURE $5.35
- Resistance Level
- INV N/A
- QURE $7.28
- Average True Range (ATR)
- INV 0.00
- QURE 0.50
- MACD
- INV 0.00
- QURE 0.04
- Stochastic Oscillator
- INV 0.00
- QURE 85.75
About INV INNVENTURE INC
Innventure Inc creates, funds, operates, and rapidly scales companies in strategic collaboration with MNCs. It provides company creation, corporate strategy, technology optimization, operations, commercialization, and funding. Innventure analyzes the market, including proprietary data provided by MNCs, to identify where their well-protected, breakthrough technologies address market needs and have the potential to create $1B+ in new enterprise value.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.